Chemical subgroup
L04AG – Monoklonale Antikörper
11Decisions
20Patient groups
Added benefit by patient group
- Considerable1
- Minor3
- Non-quantifiable2
- Not proven14
Decisions, newest first
- 2026-09-03UpliznaInebilizumabNot proven: 2 of 2 patient groups
- 2026-09-03UpliznaInebilizumabNon-quantifiable
- 2026-08-20TepezzaTeprotumumabNot proven: 3 of 3 patient groups
- 2024-08-01BriumviUblituximabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19UpliznaInebilizumabNot proven
- 2022-10-06SaphneloAnifrolumabNot proven
- 2022-09-01EntyvioVedolizumabNot proven
- 2020-05-14BenlystaBelimumabNon-quantifiable
- 2018-08-02OcrevusOcrelizumabMinor: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2015-01-08EntyvioVedolizumabNot proven: 4 of 4 patient groups
- 2012-08-02BenlystaBelimumabConsiderable
Data status: 2026-10-29